Jan 11, 2023 / 05:00PM GMT
James Daniel Gordon - JPMorgan Chase & Co, Research Division - Senior Analyst
Good morning. I'm James Gordon, JPMorgan European Pharma and Biotech analyst. And today, I've got the pleasure of introducing the Genmab presentation. So you're going to hear from Genmab's CEO, Jan van de Winkel, and then we can have a Q&A here afterwards for the further 20 minutes. Thanks a lot for joining us today, Jan. Looking forward to the presentation.
Jan G.J. van de Winkel - Genmab A/S-Co-Founder - President & CEO
Thank you very much, James. It's really a pleasure to join you all again at the annual JPMorgan Healthcare Conference as we kick off 2023. So slides from today's presentation will be available for download at our website immediately after the event. Let's get started. I think I can do that myself.
Forward-looking statements. As you are aware, this presentation may contain forward-looking statements and as such, contain certain risks and uncertainties, as you're all familiar with.
Genmab A/S at JPMorgan Healthcare Conference Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers